NCT04757363 - A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Esophagogastric CancerHER2-Negative

Interventions

DRUG

regorafenib

regorafenib (80 mg on days 1-21 of the 28-day cycle)

DRUG

nivolumab

nivolumab (240 mg on days 1 and 15 of the 28-day cycle).

DRUG

FOLFOX chemotherapy with oxaliplatin

FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale